Biotech Co.


Pharma Co.


Type/Product Area


Amount


Terms/Details (Date)

Abgenix Inc.

BASF Bioresearch
(unit of BASF AG:Germany)

Research collaboration; BASF will utilize Abgenix's XenoMouse technology to develop fully human antibodies to an undisclosed antigen target

ND

Abgenix receives up-front payment and could receive additional fees and milestones, plus royalties on future product sales (3/99)

Abgenix Inc.

Japan Tobacco Inc.

Clinical trial support related to marketing agreement for ABX-IL8, a fully human antibody generated by Abgenix using its XenoMouse technology

ND

Japan Tobacco will support Abgenix's clinical trials and will be able to use the data to support regulatory filings in its marketing areas in Japan, Taiwan and Korea (6/99)

Access Pharmaceuticals Inc.

Block Drug Co.

License agreement granting Access rights to Block's amlexanox (FDA-approved for aphthous ulcers) for use in chemotherapyand radiation-induced mucositis; IND filed in indication

ND

Access to make up-front licensing payment and will make further payments based upon achievement of milestones; Access has no ongoing royalty obligations; agreement subject to receipt of final written consent from Takeda Chemical Industries Ltd. (Japan) (1/99)

Aclara BioSciences Inc and PE BioSystems (unit of PE Corp.)

R.W. Johnson Pharmaceutical Research Institute (PRI; subsidiary of Johnson & Johnson)

PRI signed on as first Technology Access Partner for a a program to develop an ultra-high-throughput screening platform using microfluidic devices; project combines Aclara's expertise in microfluidics and PE's in electrophoresis and systems engineering

ND

PRI gains early access to advanced prototypes; further terms ND (5/99)

Affymetrix Inc.

SmithKline Beecham plc (UK)

Licensing agreement allowing SKB to make and use mechanically fabricated nucleic acid arrays for gene expression monitoring experiments conducted as part of internal research efforts

ND

SKB will pay annual usage fee linked to the number of array-based experiments performed at its sites worldwide (4/99)

Affymetrix Inc.

SmithKline Beecham plc (UK)

EasyAccess Silver agreement, giving SKB preferential access to standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in R&D

ND

EasyAccess is a volume pricing arrangement designed for large organizations (4/99)

Affymetrix Inc.

Sankyo Co. Ltd. (Japan)

Technology access/ access to GeneChip arrays and related technology for gene-expression monitoring

ND

Under EasyAccess Silver agreement, Sankyo gains broad access to GeneChip technology (11/99)

Agennix Inc.

Santen Pharmaceutical Co. Ltd. (Japan)

Development of Agennix's recombinant human lactoferrin in the treatment of dry eye disease

$5.9M

Agennix to receive up to $5.9M plus royalties on net sales; Santen receives exclusive worldwide marketing rights (2/99)

Alexion Pharmaceuticals Inc.

Procter & Gamble

Collaboration to develop and commercialize Alexion's lead C5 complement inhibitor, 5G1.1-SC, currently in Phase IIb trials for patients undergoing cardiopulmonary bypass

$95M

Alexion to receive up to $95M in total payments, including up to $39M in precommercialization milestones; Alexion retains rights to commercial manufacturing and co-promotion in the U.S. (1/99)

AlphaGene Inc.

NEN Life Science Products

AlphaGene to develop Micromax System, gene expression arrays on glass slides; product is an integrated system of microarrays and reagents needed for differential gene expression analysis, including NEN's TSA signal amplification system and AlphaGene's FLEX (full-length expressed gene technology)

ND

Long-term agreement providing NEN exclusive marketing rights to Micromax System, with four microarrays planned for 1999; further details ND (3/99)

AltaRex Corp. (Canada)

Purdue Pharma LP

Option agreement giving Purdue opportunity to license OvaRex MAb and BrevaRex MAb, both of which are anticancer immunotherapeutic monoclonal antibody products

$103.4M ($3.4M equity)

If the option is exercised, Purdue could pay in excess of $100M over 3 years in R&D support and milestone payments; AltaRex would also receive royalties on sales; Purdue also purchased $3.4M in AltaRex equity (5/99)

Alteon Inc.

Taisho Pharmaceutical Co. Ltd. (Japan)

License agreement/ Alteon's lead crosslink breaker, ALT-711

ND

Taisho was granted an exclusive option through 12/99 to acquire a license to ALT-711 for Japan, South Korea, Taiwan and China; financial details ND (9/99)

The Althexis Company Inc.

Pliva d.d. (Croatia)

Collaboration to develop and commercialize antibiotics using Althexis' structure-based design technologies

$14.4M

Althexis to receive up to $14.4M over 3 years in research funding and milestone payments; Pliva receives worldwide marketing rights to any drugs resulting from research focused on 2 specified antibacterial targets, with the exceptions of Japan, South Korea and Taiwan, where Althexis retains rights, and China, where the partners will co-promote (3/99)

AMRAD Corp. Ltd. (Australia) and the Ludwig Institute for Cancer Research (Zurich)

RPR Gencell (division of Rhone-Poulenc Rorer)

Rhone-Poulenc licensed VEGF-B (vascular endothelial growth factor B) gene patents and technology for use in cardiovascular disease

ND

ND (3/99)

AMRAD Corp. Ltd. (Australia)

Glaxo Wellcome plc (UK)

AMRAD to supply rapid point-of-care diagnostic tests for companion marketing with Glaxo hepatitis B medicines, including Zeffix (lamivudine)

ND

Glaxo will purchase HBV test for sale and marketing under Glaxo Wellcome name (2/99)

Amylin Pharmaceuticals Inc.

Linco Research Inc.

License agreement/ proprietary antibodies developed by Amylin

ND

Amylin granted Linco exclusive rights for the use of its proprietary antibodies to develop immunoassay kits for the measurement of the hormones amylin and glucagon-like peptide; immunoassay kits developed by Linco may be manufactured and distributed by Linco; Amylin received an undisclosed credit to purchase kits or services from Linco; Amylin retains the right to use the licensed antibodies for its research activities (9/99)

AnalytiCon AG (Germany)

Bayer AG (Germany)

Research collaboration/ AnalytiCon's separation and structure elucidation technologies

DM6M (US$3.18M)

Analyticon will use its separation and structure elucidation technologies to isolate, purify and characterize novel natural products from biomaterials proprietary to Bayer (9/99)

Anesta Corp.

Novartis AG (Switzerland)

Option agreement on Anesta's Oral Transmucosal System for drug delivery; option combines system with undisclosed compounds that may lead to 1 or more product candidates

ND

Partners will assess potential products, with the goal of identifying those worthy of licensing agreement (2/99)

Antex Biologics Inc.

Pfizer Inc.

Research collaboration/ Antex's antigen receptor and nutriment signal transduction platform technologies

ND

Antex's platform technologies will be used by Pfizer for the development of animal vaccines; further details ND (9/99)

ArQule Inc.

Bayer Corp. (Germany)

Research and development collaboration/ Arqule's Custom Array program

$30M

ArQule will produce compounds for screening against Bayer's therapeutic and agrochemical targets; Bayer will receive arrays designed to its specifications over a period of three years, and will own all rights to the compounds resulting from the collaboration; ArQule will receive $30M in cash payments over the term of the agreement as compound delivery goals are met (10/99)

ArQule Inc.

Pfizer Inc.

Research and technology license agreement/Arqule's AMAP chemistry operating system

$117M

ArQule will devote designated technologies, scientists and its AMAP system to generate compound libraries for Pfizer; ArQule could receive up to $117M over the 4.5-year term of the collaboration (7/99)

Atugen Biotechnology GmbH (Germany)

AstraZeneca Group plc (UK)

Research collaboration/ Atugen's target validation services

ND

Astra will provide Atugen with gene targets and cell lines of interest for in vitro screening and delivery optimization; Atugen will develop GeneBloc reagents to knock down the genes of interest; Atugen will perform quantitative RNA analysis and technology transfers; Astra has the option to receive validated GeneBlocs against their targets for in vivo validation; financial terms ND (8/99)

Aurora Biosciences Corp.

F. HoffmannLa Roche Ltd. (Switzerland)

Aurora will provide a dedicated screen development and technology transfer resource to Roche; deal covers development of screens for up to 12 Roche targets in the first year

ND

Roche will make payments for screen development, technology transfer services and licenses, and will also make R&D payments to Aurora for compounds identified through screens generated in the collaboration, and royalties upon commercialization of compounds (2/99)

Aurora Biosciences Corp.

Pharmacia & Upjohn Inc.

Aurora to provide assay development and screening services to P&U; initial focus is to develop assays using Aurora's high-sensitivity fluorescent assay technology for a number of orphan G-protein-coupled receptors identified by P&U; Aurora will also screen P&U compound libraries for hits

ND

P&U will fund a dedicated assay development team at Aurora; Aurora will provide screening services for some of the assays developed for P&U at a predetermined minimum level and for a separate fee; Aurora could also receive milestones and royalties (2/99)

Aurora Biosciences Corp.

Becton Dickinson and Co.

Research collaboration; Becton Dickinson will use Aurora's GenomeScreen technology to identify genes useful as drug screening targets

ND

Becton Dickinson will provide research support funds, and the parties will evaluate opportunities for future commercialization (3/99)

Aurora Biosciences Corp.

Glaxo Wellcome plc

Research collaboration/ion channel drug discovery through access to Aurora's ion channel technologies

ND

Three-year agreement under which Aurora will provide access to its ion channel technology, including its voltage ion probe reader, the VIPR, its voltage sensor dyes and related assay technology; Aurora will supply assay development, instrumentation and other support (12/99)

Aurora Biosciences Corp.

Merck & Co. Inc.

Research collaborations/ functional genomics research using Aurora's Genome Screen technology to investigate cell signaling pathways and gene function related to selected Merck therapeutic programs

ND

Merck will receive a license to use the data and materials resulting from the program in basic research and drug discovery; Aurora will receive an up-front payment, with the potential for milestones and additional revenues if products are commercialized based on the technology (11/99)

Aurora Biosciences Corp.

Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Products Corp.)

Research collaboration/ion channel drug discovery through access to Aurora's ion channel technologies

ND

Five-year agreement under which Aurora provides access to its ion channel technology, including its voltage ion probe reader, the VIPR, its voltage sensor dyes; Aurora will develop assays for specified ion channels for Wyeth, will deliver instrumentation and will provide ongoing scientific and technical support; financial details ND (12/99)

AutoImmune Inc.

Teva Pharmaceutical Industries Ltd. (Israel)

Teva will use AutoImmune's technology for oral immune modulation to develop an oral formulation of Copaxone (glatiramer acetate) for multiple sclerosis and a product to treat myasthenia gravis

$20M

Teva to pay milestones upon product approvals and escalating royalties based on cumulative sales for all products covered by the agreement (2/99)

Avant Immunotherapeutics Inc.

Pasteur Merieux Connaught (a unit of RhonePoulenc SA; France)

Clinical trial collaboration/ Avant's adjumer delivery system

ND

Avant and Pasteur will collaborate to evaluate the safety and immunogenicity of an adjumer-formulated respiratory syncytial virus vaccine in a Phase I trial; Avant previously received a milestone payment upon initiating the trial (8/99)

Aviron

Wyeth Ayerst Laboratories (wholly owned subsidiary of American Home Products)

Worldwide collaboration for the marketing of FluMist, Aviron's intranasal influenza vaccine

$400M

Wyeth Lederle Vaccines business unit gains exclusive worldwide marketing rights; Wyeth and Aviron will co-promote in the U.S., while Wyeth has exclusive rights elsewhere, excluding Korea, Australia, New Zealand and certain South Pacific countries; companies will collaborate on regulatory, clinical and marketing programs; Aviron receives initial license payment of $15M, $15M upon acceptance for filing of NDA, and $20M upon FDA approval; the granting of certain other rights under the license would trigger additional payments in excess of $140M; consideration also includes up to $40M in financing, contingent upon product approval; Aviron will also receive about 40% of product revenues from Wyeth in the form of transfer payments and royalties, which increase at higher sales levels; Aviron will incur expenses to supply and co-promote FluMist (1/99)

Axis Genetics

F. HoffmannLa Roche Ltd. (Switzerland)

Collaboration to evaluate oral Epicoat vaccines for use in the field of animal nutrition and health applications; partners seeking to determine whether oral administration of the vaccines, created with Axis' Chimeric Virus Particle technology, can stimulate mucosal immunity in the gastrointestinal tract of farm animals

ND

Agreement includes a fee-bearing option for Roche to obtain a license for use in animal nutrition and health applications; further details ND (3/99)

Axonyx Inc.

Ares Serono (Switzerland)

R&D collaboration centered on Axonyx's peptide technology with potential to treat neurodegenerative diseases; Claudio Soto will join the Serono Pharmaceutical Research Institute in Geneva to conduct preclinical development and trials of patented peptides he originally identified

$22.5M

Ares Serono gains exclusive rights to any drug candidates that emerge from the program; Axonyx receives an initial payment of $0.25M and could receive up to $22.5M, plus royalties, if Ares Serono opts for a structured licensing agreement after the 1st or 2nd year of the collaboration; Ares Serono will pay both direct and indirect costs of development work at its Geneva facility (5/99)

Axys Pharmaceuticals Inc.

Rhone-Poulenc Rorer

Axys to provide generic compound screening library consisting of multiple small-molecule synthetic organic compound libraries created using Axys' combinatorial chemistry technologies

ND

2-year agreement is second between Axys and RPR; terms ND (1/99)

Bio-Discovery Ltd. (UK)

ZymoGenetics Inc. (a Seattlebased subsidiary of Novo Nordisk A/S; Denmark)

Development agreement/ Bio-Discovery's complement inhibitor B-D001

ND

Bio-Discovery and ZymoGenetics signed an agreement to develop and commercialize Bio-Discovery's B-D001 for the prevention of reperfusion injury; Zymo receives a 12month exclusive option period to evaluate the compound; if the option is exercised, Zymo would be responsible for funding all further clinical development and marketing; upon exercise of the option, Zymo would receive an exclusive, worldwide license to develop, manufacture and market B-D001 as a therapeutic agent; Bio-Discovery could receive undisclosed exercise fees, milestone payments and royalties (10/99)

Bio-Technology General Corp.

Diosynth (wholly owned subsidiary of Akzo-Nobel NV; the Netherlands)

Technology transfer and license agreement for BTG's recombinant human insulin

ND

BTG will transfer technology to Diosynth, which will manufacture the product in bulk form for licensed territories (most of the world); Akzo Nobel's Organon subsidiary may finish the bulk and market the product; BTG will receive license fees, milestones and royalties (1/99)

Bio-Technology General Corp.

Teva Pharmaceutical Industries Ltd. (Israel)

Development agreement/Bio-Technology's development technologies

$20M

Bio-Technology will develop and manufacture generic recombinant therapeutic products; Teva will pay up to $20M for product rights and milestone payments (10/99)

Biovector Therapeutics SA (France)

Bayer AG (Germany)

Feasibility agreement under which Bayer will assess Lipoplex-Biovector Systems to allow functional circulating Factor VIII protein expression

ND

Study expected to last 6 months; further details ND (3/99)

Boston Life Sciences Inc.

Pfizer Inc.

Development and license agreement/Boston Life's C-Maf technology

ND

Pfizer will screen its small-molecule collection for potential inhibitors of C-Maf to develop a small-molecule therapeutic for allergies and asthma; Boston Life will receive an undisclosed initial payment and royalties on eventual sales of any product resulting from the collaboration (9/99)

Caliper Technologies Corp.

Eli Lilly and Co

License agreement/ Caliper's high-throughput screening technology access program

ND

Eli Lilly will have access to high-throughput screening technologies and products based on Caliper's LabChip microfluidics platform; Lilly will participate in the development of successive generations of the LabChip technology; financial details ND (8/99)

Cambridge Antibody Technology (UK)

AstraZeneca Group plc (UK)

Research collaboration/ Cambridge's ProAb and ProxiMol platform technologies

ND

Cambridge will use its ProAb technology to isolate and provide antibody-based research reagents specific for cell-surface receptors and intracellular targets provided by AstraZeneca; Cambridge will use its ProxiMol technology to generate biologically active antibodies to explore the function of a number of receptors; Cambridge will receive revenues from AstraZeneca and will retain all rights to develop and commercialize any antibodies generated from the collaboration (9/99)

Cambridge Antibody Technology (UK)

Searle (pharmaceutical business of Monsanto Co.)

Development collaboration/fully human monoclonal antibodybased drugs across multiple disease areas, focusing particularly on the field of cancer

$212M

CAT could receive up to $212M through a $12.5M up-front equity investment, a minimum of $14.5M in research funding, another $35M in various fees and milestones and an additional $150M based on clinical development and regulatory milestones; CAT will also receive royalties on sales of both antibody-based drugs and small-molecule drugs developed by Searle when CAT technology is used to validate a target; both companies will contribute technology, intellectual property and expertise to the project, with CAT generating antibodies to Searle targets (12/99)

Celera Genomics

Pfizer Inc.

Database subscription and research collaboration/access to all of Celera's database products and collaboration to discover target genes derived from Celera's sequencing of the human genome

ND

Five-year agreement; Pfizer's access to Celera's isolated full-length genes is non-exclusive; financial details ND (11/99)

Celera Genomics

Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France)

Gene discovery agreement/Celera's GeneTag technology

ND

Celera will identify therapeutic targets for various diseases by applying its GeneTag technology to Rhone-Poulenc's disease model systems; Rhone-Poulenc will pay upfront fees, milestones and royalties upon commercialization of any drugs resulting from the agreement; Rhone-Poulenc has the option to access Celera's capabilities for full-length cDNA cloning and functional characterization of candidate genes; financial details ND (7/99)

Celera Genomics

Novartis AG (Switzerland)

Database subscription and access agreement; Novartis receives subscription to 3 databases being devel oped by Celera - the Human Gene Index, the Drosophila Genome Database and the Human Gene Genome Database; Novartis also gains access to associated bioinformatics tools

ND

Novartis will retain all rights to any discoveries it makes using the databases, and will provide input into development of Celera's products; agreement is for 5 years (4/99)

Cell Pathways Inc.

Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France)

Clinical trial collaboration/ Cell Pathways' Aptosyn and Rhone-Poulenc's Taxotere

ND

The companies will collaborate in clinical trials investigating the therapeutic potential of Aptosyn (exisulind) in combination with Taxotere (docetaxel) in previously untreated non-small-cell lung cancer; each company will retain all marketing rights to its respective products; further details ND (9/99)

Celtrix Pharmaceuticals Inc.

Elan Corp. plc (Ireland)

Establishment of a joint venture to develop Celtrix's SomatoKine (recombinant insulin-like growth factor-1 and its major binding protein) for osteoporosis

$15.3M (entire amount is equity investment)

Elan will buy $12.9M in preferred Celtrix stock at $2.06 per share, a significant premium, and will own 19.9% of the joint venture; Elan may convert the preferred stock to Celtrix common stock or exchange a portion for a larger share of the venture; Elan separately purchased $2.5M worth of Celtrix stock at an undisclosed premium (4/99)

CeNeS Ltd. (UK)

Glaxo Wellcome plc (UK)

Development and commercialization collaboration on Glaxo's sipatrigine, a potential stroke treatment that has passed Phase II trials

ND (equity component ND)

CeNeS will acquire, for a license fee and milestone payment, an exclusive license for the drug; CeNeS will fund and be responsible for future development; however, Glaxo retains an option to commercialize the product once Phase III trials are complete; if Glaxo waives the option, CeNeS may commercialize or sublicense; Glaxo will purchase CeNeS equity as part of the deal (4/99)

Centocor Inc.

Eli Lilly and Co.

Partnership to create Acute Coronary Syndromes registry, a registry and database to follow patients with acute coronary syndrome from symptom onset through outcome; goal is to define optimal treatment strategies; PharmedicaResearch Inc. will manage the registry

ND

ND (6/99)

Cephalon Inc.

Schwarz Pharma (Germany)

Licensing agreement/ tyrosine kinase inhib itors for treating prostate and other cancers; includes two compounds in clinical development

ND

Schwarz will develop and market compounds in Europe and several other territories outside the U.S.; Cephalon will receive up-front license fee, milestones and transfer price on products it manufactures (12/99)

Cerep SA (France)

Pfizer Inc.

Drug discovery research collaboration under which Pfizer will use Cerep's highthroughput profiling and high-throughput lead development technologies for lead and preclinical optimization purposes, respectively

ND

Agreement is for 3 years; further details ND (5/99)

Cerep SA (France)

Bristol Myers Squibb Co.

R&D collaboration/Cerep's BioPrint database

$43M

The collaboration agreement spans five years, with an option for Bristol to terminate after three years; Bristol will have non-exclusive access to the BioPrint database and tools; Cerep will carry out high-throughput profiling of Bristol compounds currently in the lead development process; Cerep and Bristol will develop and share technologies related to assay miniaturization for compound profiling; research funding and potential milestone payments could exceed $43M, and will include an equity stake by Bristol of $3M; Cerep will receive royalties on any products resulting from the collaboration (7/99)

Cetek Corp.

Pharmacia & Upjohn Inc.

Screening agreement/ Cetek's proprietary screening technology

ND

Cetek will develop assays for Pharmacia's targets and screen them against Pharmacia's compound libraries; further details ND (9/99)

ChemBridge Corp.

F. HoffmannLa Roche (Switzerland)

Technology access agreement/ChemBridge's PharmaCore combinatorial lead discovery library

ND

ChemBridge entered a three-year agreement to provide Roche access to its PharmaCore library, which will be provided on a nonexclusive basis to all six Roche research centers in Switzerland, Germany, Japan, the UK and the U.S.; financial details ND (10/99)

ChemRx (subsidiary of Discovery Partners International)

DuPont Pharmaceuticals Co.

Chemical libraries development agreement; ChemRx will develop multiple classes of compounds for DuPont's drug-discovery and lead-optimization programs

ND

ChemRx will develop and produce compounds on a fee-for-service basis, and will provide the compounds to DuPont on an exclusive basis with no milestone or royalty obligations (6/99)

ChemRx (a subsididiary of Discovery Partners Int'l)

The pharmaceutical division of Kirin Brewery Co. Ltd. (Japan)

Research agreement

ND

ChemRx will develop multiple lead classes of compounds for Kirin's optimization libraries on a fee-for-service, exclusive basis for screening in Kirin's internal assays; there are no milestone or royalty obligations under the agreement; further financial details ND (9/99)

ChemRx (a subsidiary of Discovery Partners Int'l)

Pharmacia & Upjohn

Research agreement

ND

ChemRx will develop multiple classes of compounds for P&U's drug discovery and lead optimization libraries on a fee-for-service, exclusive basis for screening in P&U's internal assays; there are no milestone or royalty obligations under the agreement; further financial details ND (10/99)

Chiron Corp.

Abbott Laboratories

License agreement/ Chiron's hepatitis C patents

ND

Chiron will license its hepatitis C patent rights for use in nucleic acid diagnostics; the worldwide, semi-exclusive license grants Abbott the right to research, develop, manufacture and sell HCV nucleic acid probe products for in vitro diagnostics; Chiron will retain the right to grant limited additional licenses to others, and will receive an up-front license fee upon signing and a milestone payment upon first commercial sale of a licensed product; Chiron will also receive royalties on the sale of licensed products (9/99)

Chiron Corp.

Kyokuto Seiyaku Kogyo Inc. (Japan)

Patent litigation settlement/hepatitis C virus immunodiagnostics and antigenic polypeptides

ND

Kyokuto is now prohibited from any manufacture, sale or distribution of HCV antigens or test kits (10/99)

CoCensys Inc.

Senju Pharmaceutical Co. Ltd. (Japan)

Collaboration to explore potential ophthalmic indications of glycine-site NMDA and AMPA receptor antagonist compounds

ND

ND (2/99)

CoCensys Inc.

Senju Pharmaceutical Co. Ltd. (Japan) and the Parke-Davis Pharmaceutical division of WarnerLambert Co.

Collaboration to investigate subtype-selective NMDA receptor antagonist compounds that are being developed for neurological and psychiatric disorders under CoCensys' collaboration with Parke-Davis

ND

ND (2/99)

Columbus Molecular Software Inc.

Pfizer Inc.

Research collaboration centering on development and use of LeadScope, Columbus Molecular's chemistry-based decision support system to identify drug candidates

ND

Pfizer will provide data, product development guidance and initial funding; Columbus Molecular will license to Pfizer its software and computational models for use with Pfizer's compound libraries (6/99)

CombiChem Inc.

Ono Pharmaceutical Co. Ltd. (Japan)

CombiChem will work with Ono to generate lead drug candidates for a target of interest to Ono; target was selected using CombiChem's Universal Informer Library

ND

Ono will pay a project initiation fee, research support and milestones; Ono has exclusive global rights to develop and market or sublicense products resulting from the collaboration; CombiChem is entitled to royalties on resulting products (1/99)

Connetics Corp.

Medeva plc

Development, commercialization and supply agreement for ConXn (recombinant human relaxin)

$35M (equity; 3-4%)

Medeva will pay $8M on closing (including $4M development fee and $4M equity investment), $17M in milestones for U.S. and European progress, $5M for development and approval of each indication in Europe in addition to scleroderma, and $10M of U.S. product development costs; Medeva is responsible for development and commercialization in Europe; companies will share U.S. co-promotion rights for up to 5 years; Medeva will purchase relaxin materials from Connetics (1/99)

Connetics Corp.

Soltec Research Pty Ltd. (Australia, a unit of F.H. Faulding & Co. Ltd.)

License agreement/ Soltec's ketoconazole foam

ND

Connetics received exclusive, worldwide rights (exluding Australia and New Zealand) to develop, market and manufacture ketoconazole foam, a quick-break foam formulation of the antifungal dermatologic drug, ketoconazole; financial details ND (7/99)

Corixa Corp.

Zambon Group spa (Italy)

Research collaboration and license agreement to support Corixa's development of lung cancer vaccines

$21.5M (equity purchase of $2M)

Zambon gains exclusive rights to vaccine products aimed at treating lung cancer in Europe, the countries of the former Soviet Union, Argentina, Brazil and Colombia, as well as co-exclusive rights in China; Corixa may receive more than $21.5M in license fees, research funding and milestone payments; total includes $2M purchase of Corixa common stock at a premium to the market (5/99)

Corixa Corp.

Japan Tobacco Inc. (Japan)

Research collaboration and license agreement to support Corixa's development of therapeutic lung cancer vaccines

$40M

Japan Tobacco gains exclusive rights in Japan and North America as well as co-exclusive rights with Zambon Group spa (see previous entry) in China; Corixa may receive over $40M in license fees, research funding and milestone payments, plus royalties; a “significant percentage“ of potential payments is guaranteed (6/99)

Corixa Corp.

Zenyaku Kogyo Co. Ltd. (Japan)

License, R&D agreement/ Corixa's PVAC therapeutic

ND

Corixa and Zenyaku entered a multi-year license, research and development agreement for PVAC, a psoriasis immunotherapeutic; Zenyaku receives exclusive rights in Japan, while Corixa and its partner, Genesis Research and Development Corp., retain exclusive rights with respect to the rest of the world; Corixa will receive license fees, research funding and milestone payments based on successful clinical and commercial progress, as well as a royalty stream on future product sales; further financial details ND (8/99)

Cortex Pharmaceuticals Inc.

NV Organon (pharmaceutical business unit of AkzoNobel NV; the Netherlands)

Exclusive worldwide license agreement that will enable Organon to develop and commercialize Cortex's Ampakine technology for the treatment of schizophrenia and explore it in the area of depression

ND

Agreement includes an up-front payment, R&D payments for 2 years, and milestone payments, plus royalty payments on worldwide sales (1/99)

Cortecs plc (UK)

SmithKline Beecham plc (UK)

License agreement/ antigen technology for the development and commercialization of vaccines to prevent diseases caused by Haemophilus influenzae and Moraxella cattarhalis in children

ND

Cortecs will receive an up-front payment, milestones and royalties on sales (11/99)

Cubist Pharmaceuticals Inc.

Novartis Pharma AG (Switzerland)

Novartis to use Cubist's VITA technology (Validation in vivo of Targets and Assays for Anti-infectives) to validate and develop assays for anti-infective targets and to identify new compounds for development as anti-infective agents

$33M (equity; 5%)

Novartis to make up-front $4M equity investment in Cubist; Novartis will also provide research funding annually for 3 years, make milestone payments for each high-throughput screen delivered to Novartis and milestone payments for each product developed (2/99)

CuraGen Corp.

F. Hoffmann La Roche Ltd. (Switzerland)

Target discovery and pharmacogenomics collaboration; Roche will use CuraGen technology to evaluate product candidates, discover drug targets and facilitate development of drugs and diagnostics; CuraGen will provide Roche research centers with access to its gene expression and gene sequence databases through CuraGen's Internet-based platform; deal includes use of CuraGen's GeneCalling and SeqCalling technologies for identification of genes and generation of coding sequences within expressed genes

ND

Agreement includes up-front funding and potential milestones and royalties; agreement is for two years and is renewable (3/99)

deCODE Genetics (Iceland)

Roche (Switzerland)

License agreement/ deCODE's GeneMiner software

ND

Roche will license deCODE's GeneMiner bioinformatics software for the rapid identification of disease-relevant genes in its internal programs; further details ND (9/99)

Deltagen Inc.

Roche Bioscience (unit of F. Hoffmann La-Roche Ltd.; Switzerland)

Research agreement under which Deltagen will create knockout mice for up to 10 Roche gene targets for use in target validation programs

ND

ND (1/99)

Deltagen Inc.

Merck & Co. Inc.

Research agreement under which Deltagen will provide target validation using knockout mouse technology

ND

ND (1/99)

Dendreon Corp.

Kirin Brewery Co. Ltd. (Japan)

Research and license agreement for development of dendritic cell cancer therapies; Kirin will support Dendreon's research on dendritic cells, with a focus on developing immunotherapies for cancers most prevalent in Asian markets

ND

Kirin will provide research funding and gains rights to any resulting products in Asia and Oceania; companies will jointly market products in Europe, and Dendreon has U.S. rights (5/99)

DepoMed Inc.

Elan Corp. plc (Ireland)

Joint venture/gastric retention oral delivery technologies and development of products using those technologies

$5M

Companies will create joint venture to develop delivery technologies and develop products in undisclosed areas; Elan will invest $5M in DepoMed's common stock and provide R&D funding to the JV (12/99)

Destiny Pharma (UK)

Ciba Vision Corp. (unit of Novartis AG; Switzerland)

Co-development agreement; photodynamic therapy for ophthalmic diseases

ND

Ciba gains exclusive global rights to develop photodynamic therapy for ophthalmic diseases; Ciba will pay a series of milestones and royalties and will take over development once the current research program is completed; Destiny retains rights to all other indications (11/99)

diaDexus LLC (joint venture between Incyte Pharmaceuticals Inc. and SmithKline Beecham plc)

SmithKline Beecham Corp. (unit of SmithKline Beecham plc)

SmithKline exclusively licensed rights to develop and perform a PLA2 test, which determines whether prostate cancer has spread

ND

SmithKline gains certain exclusive rights in the U.S. and several international markets to develop and perform clinical laboratory testing for PLA2; diaDexus will receive licensing fees as well as royalties on sales (2/25)

Discovery Therapeutics Inc.

Fujisawa Healthcare Inc.

Development and license agreement/Discovery's selective adenosine A1 agonist, DTI-0009

ND

Both companies will collaborate in the development of the injectable form of DTI0009 for the treatment of cardiac conditions associated with abnormally high heart rates; Fujisawa will have exclusive North American development and marketing rights to an injectable form of the A1 agonist for the treatment of paroxysmal supraventricular tachycardia, and for rate control in atrial fibrillation and atrial flutter; additionally, Fujisawa will have exclusive marketing and promotion rights in the U.S. and Canada to all other injectable indications developed by Fujisawa for DT-0009 and certain back-up compounds; Discovery retains foreign rights to the injectable products; financial details ND (8/99)

Dyax Corp.

Pasteur Merieux Connaught (unit of Rhone-Poulenc SA; France)

Development collaboration/use of Phage Display technology to develop affinity ligands to provide purification of PMC's vaccines

ND

PMC will fund the research and Dyax will receive milestone payments and royalties on resulting products (10/99)

Epoch Pharmaceuticals Inc.

PE BioSystems (division of Perkin-Elmer Corp.)

PE licensed genetic analysis technology from Epoch and will purchase Epoch's proprietary chemical intermediates

ND

Perkin-Elmer will pay up-front license fees and pre-payments for future purchases, along with royalties on products incorporating the technology (1/99)

Evotec Biosystems AG (Germany)

Pfizer Inc.

Technology license and access agreement; Pfizer gains access to Evotec's ultra-high-performance screening technology (called EVOscreen) and a non-exclusive, worldwide license to use Evotec hardware and software

$17M ($1M equity investment)

Evotec will receive $16M, including a technology access fee and research payments; Pfizer will make a $1M equity investment in Evotec upon delivery of the 1st hardware system; agreement is for 3 years (6/99)

Exelixis Pharmaceuticals Inc.

Bristol-Myers Squibb Co.

Research collaboration/ identification of validated targets

ND

The companies entered a three-year collaboration to identify novel validated targets for new medicines using model system genetics; Exelixis will use its proprietary technology to determine the molecular targets of compounds provided by Bristol; Bristol will provide Exelixis with research funding and additional payments subject to the achievement of research and commercialization milestones; Exelixis will contribute to the work of Bristol's internal department of applied genomics; the companies will exchange certain core technologies; Bristol will acquire Exelixis technology, including a sublicense to the patented P-element technology, tools to manipulate genes in Drosphila and C. elegans, and access to the Drosophila proprietary EST database, FlyTag; Exelixis will acquire BMS' lead optimization technology (9/99)

Exelixis Pharmaceuticals Inc.

Pharmacia & Upjohn

Research collaboration to identify targets for smallmolecule therapeutics in the areas of Alzheimer's disease and metabolic syndrome, including diabetes and obesity; Exelixis will utilize PathFinder technology coupled with genomic and computational biology techniques to identify targets

ND

Collaboration is for 5 years; Exelixis will receive an up-front payment, research support, and royalties on sales; Exelixis retains rights to develop smallmolecule therapeutics outside the field of the sponsored research as well as in the field(s) of research for targets not selected by P&U (3/99)

ExonHit Therapeutics SA (France)

Sosei Co. Ltd. (Japan)

Sosei to serve as R&D partner and independent, nonexclusive adviser to ExonHit in negotiating commercial partnerships with Asian companies covering any or all of research, development, manufacture, marketing and distribution activities for ExonHit's genomic products, including gene profiling; ExonHit will also use its DATAS (Differential Analysis of Transcripts Alternatively Spliced) technology on ôme tooö molecules from Japanese companies to highlight how the molecules differ from competing compounds

ND

ND (2/99)

FibroGen Inc.

Taisho Pharmaceuetical Co. Ltd. (Japan)

Development agreement/ human monoclonal antibodies

ND

FibroGen and Taisho entered an agreement to develop and commercialize human monoclonal antibodies for the treatment of fibrotic kidney diseases; Taisho will provide funding in the form of equity purchases, benchmark payments and one-half of the global preclinical and clinical development costs outside the Pacific Rim, where Taisho will fund all the clinical and development costs; additionally, Taisho will pay FibroGen royalties on sales of therapeutic antibody products in Japan, China, Taiwan, Korea and the countries of Southeast Asia; FibroGen will retain commercialization rights in North America, Europe and the rest of the world (9/99)

Flamel Technologies (France)

Novo Nordisk A/S (Denmark)

Licensing and development agreement/Basulin, Flamel's long-acting basal insulin product for diabetes (currently in Phase I trials)

$42M

Novo acquires exclusive worldwide marketing rights; Flamel receives up-front licensing fees of $5M, plus $37M in milestones; in addition, Flamel will supply Novo with Medusa nano-particles for Basulin (12/99)

Genelabs Technologies Inc.

SmithKline Beecham plc

R&D collaboration to develop a system for regulating the expression of genes that are critical for survival or replication of certain bacteria; program will identify target sites in the DNA of bacterial genes that can be regulated by small-molecule, sequence-specific DNAbinding drugs

ND

The program is being funded by a 1-year grant from the Defense Advanced ReSearch Projects Agency, and may lead to a broader drug discovery program (4/99)

Gene Logic Inc.

Japan Tobacco Inc.

Gene Logic will use its READS gene expression and bioinformatics technologies to identify drug targets for an undisclosed therapeutic area

$12M

Gene Logic will receive a minimum of $12M in committed revenues and is entitled to milestones of about $17M for each product resulting from use of technologies, plus royalties (1/99)

Gene Logic Inc.

UCB Research Inc. (a unit of UCB Pharma)

Development agreement/ Gene Logic's READS technology and Affymetrix Inc.'s GenChip probe arrays

ND

Gene Logic and UCB will jointly develop a custom gene expression database for the discovery of new drugs for asthma and allergies; the companies also will work through a joint research committee to evaluate potential therapeutic targets resulting from the collaboration; financial details ND (9/99)

Gene Logic Inc.

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Database development/use of gene ex pression information to identify genetic targets for diabetes compounds

ND

Gene Logic will have rights to include data generated in the study in its GeneExpress databases (12/99)

Genentech Inc.

Schwarz Pharma AG (Germany)

Development and distribution agreement for Nutropin AQ (somatropin, rDNA origin, for injection) and Nutropin Depot (somatropin, rDNA origin, for depot suspension); both are growth hormones for treatment of adult and pediatric growth disorders

ND

Schwarz gains exclusive rights to import, distribute and develop Nutropin AQ and Nutropin Depot in Europe and certain other countries outside the U.S., Canada and Japan; Schwarz will file applications for both in Europe (1/99)

Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.)

Rhone-Poulenc Rorer

RPR joined GI's DiscoverEase program, which provides access to DiscoverEase protein library of human secreted proteins, the corresponding genes, and a relational database of associated information; RPR will analyze the genes and proteins to identify smallmolecule drug targets and genes and proteins with potential applications in gene therapy and vaccines

ND

ND (3/5)

Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.)

Sankyo Co. Ltd. (Japan)

Sankyo joined GI's DiscoverEase program, which provides access to DiscoverEase protein library of human secreted proteins, the corresponding genes, and a relational database of associated information; Sankyo will analyze the genes and proteins to identify smallmolecule drug targets and genes and proteins with potential therapeutic applications

ND

GI will receive an up-front library access fee and possible downstream fees based on the successful development and commercialization of therapeutics (3/99)

Genetix Pharmaceuticals Inc.

Cordis (subsidiary of Johnson & Johnson)

R&D collaboration on gene therapy products to treat cardiovascular disease by means of angiogenesis; initial phase will center on evaluation of several angiogenic genes and gene-delivery methods; research will utilize Genetix's gene transfer systems and the NOGA intracardiac navigational catheter system developed by J&J's Biosense Webster subsidiary

ND

Cordis will provide research funding to Genetix with an option to extend it in the future; Genetix would grant a royaltybearing license to Cordis to develop and market therapies (1/99)

GeneTrace Systems Inc.

Berlex Laboratories Inc. (a subsidiary of Schering AG; Germany)

Research collaboration/ GeneTrace's gene expression technology

ND

GeneTrace will combine its gene expression technology with Berlex's chemical library compounds; GeneTrace will apply its technology to the study of a number of human cancer genes provided by Berlex; Berlex will pay GeneTrace an initiation fee and additional funds upon completion of specific milestones; financial terms ND (8/99)

Genome Therapeutics Corp.

bioMerieux (France)

Technology access agreement /Genome's PathoGenome database

$6.2M

bioMerieux purchased a subscription to Genome's microbial PathoGenome database as part of an alliance to develop, manufacture and sell in vitro diagnostic products for human clinical and industrial applications; Genome granted bioMerieux all rights in the area of pathogen genetics; bioMerieux paid an up-front technology access fee and made a $3.75M equity investment in Genome's common stock; in addition, bioMerieux will fund a research program for at least four years, subscribe to the PathoGenome database and pay royalties on future products; guaranteed first-year funding, including the equity investment is approximately $6.2M; additional terms ND (10/99)

Genome Therapeutics Corp.

Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Products Corp.)

Research collaboration/development of osteoporosis therapies utilizing targets based on characterization of a gene associated with high bone mass trait, the mirror image of osteoporosis

$118M

Wyeth-Ayerst will pay Genome Therapeutics an undisclosed up-front fee, fund a multi-year research program, make milestone payments and pay royalties based on sales of therapeutic products developed from the collaboration; if the program runs full term with all milestones met, payments would exceed $118M, excluding royalties (12/99)

Genometrix Inc.

Motorola Inc.

Motorola obtained a nonexclusive license to certain fundamental DNA chip intellectual property for the commercialization of portable DNA-based diagnostic systems

ND

Combined equity financing and license option agreements; Motorola bought an undisclosed amount of Genometrix preferred stock and obtained an option for a nonexclusive license (1/99)

Genzyme Transgenics Corp.

Bristol-Myers Squibb Co.

Research collaboration/development of transgenic animals capable of producing undisclosed fusion protein being evaluated for treatment of organ transplant rejection and autoimmune disorders

ND

In the first phase, Genzyme Transgenics will receive development, milestone and maintenance fees while developing transgenic animals; if project succeeds, companies would enter supply agreements for clinical and commercial production (11/99)

GLYCODesign Inc. (Canada)

Seikagaku Corp. (Japan)

Research collaboration/identification of small-molecule, orally active Core 2 transferase inhibitors for the treatment of inflammation

$56M

Seikagaku may select for development up to 3 anti-inflammatory compounds and has the option for an exclusive, worldwide, sublicensable right to intellectual property on compounds selected; GLYCODesign will receive $8M as an up-front equity investment and research support, $16M for milestones for each compound selected and royalties on any sales (11/99)

GPC AG (Germany)

Boehringer Ingelheim Austria GmbH

Research collaboration to discover oncology genetic targets and their expression profiles; GPC will use its ExpressCode platform to elucidate gene expression profiles and contribute functional information for potential Boehringer targets

ND

ND (6/99)

GPC AG (Germany)

Hoechst Marion Roussel Deutschland GmbH (Germany)

Research collaboration to discover new antifungal targets and their biochemical pathways; GPC will use its PathCode platform to construct protein-protein interaction maps and assign functions to fungal genes identified by Hoechst

ND

ND (6/99)

ID Biomedical Corp.

Mitsubishi Chemical Corp. (Japan)

Marketing and license agreement/Velogene rapid tests for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus, as well as technology for developing additional tests

ND

Mitsubishi gains non-exclusive rights to market and distribute Velogene rapid tests for MRSA and VRE in Japan, along with a non-exclusive license to use ID's technology in Japan for the development of tests for infectious diseases from blood samples (12/99)

Igen International Inc.

Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France)

Technology access agreement/Igen's M-Series high-throughput screening system

ND

Rhone-Poulenc received access to Igen's M-Series screening systems for use in its drug screening projects; further details ND (7/99)

ILEX Oncology Inc.

Eli Lilly and Co.

ILEX will develop Lilly's diarysulfonylurea, LY295501, an anticancer compound; Lilly has option to further develop and commercialize the molecule after completion of certain clinical trials; if Lilly declines the option, ILEX gets the rights

ND

ILEX will pay Lilly milestones and royalties on sales in addition to a license fee (1/99)

ImmunoGen Inc.

SmithKline Beecham plc (UK)

SmithKline to develop and commercialize ImmunoGen's lead tumor-activated prodrug, huC242-DM1

>$40M (equity; approximately 7%)

ImmunoGen could receive up-front cash and milestones of more than $40M, plus royalties; at ImmunoGen's option, SmithKline will purchase up to $5M of common stock over the next 2 years; SmithKline receives exclusive worldwide rights to commercialize huC242-DM1, except in certain Far East territories (2/99)

Inflazyme Pharmaceuticals Ltd.

Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)

R&D collaboration on HMR's H1/NK1 inhibitor (a single molecule combining an antihistamine and a second anti-allergic mediator) and a compound from Inflazyme's IPL576 class; Inflazyme will be responsible for development of both through Phase IIa; HMR will then have the option to take over further development and commercialization of the oral form of the H1/NK1 inhibitor and the IPL576 compound; the companies will also collaborate on discovery of the mode of action and cellular target of IPL576

$91M

HMR would get worldwide rights (except Canada) for a compound from Inflazyme's IPL576 class for the treatment of respiratory disease and asthma; Inflazyme would receive a license to develop oral and topical forms of HMR's H1/NK1 inhibitor as a treatment for allergies; HMR will have the option to take over further development and commercialization of the IPL576 compound and the oral form of the H1/NK1 inhibitor (with Inflazyme retaining rights to any topical ocular formulation of the inhibitor); Inflazyme receives upfront licensing fee and equity investment by HMR totaling $16M, plus milestones of $75M and royalties; Inflazyme has rights to discoveries made in research into mode of action and target for IPL576 until HMR takes over development (2/99)

InSite Vision Inc.

Pharmacia & Upjohn Inc.

P&U licensed ISV-205, which contains diclofenac (non steroidal anti-inflammatory drug) delivered to the eye using sustained-release DuraSite technology; P&U will assume responsibility for development upon completion of Phase II studies currently being conducted by InSite

ND

InSite receives equity investment from P&U, potential future milestone-based equity investments, payments for ongoing technical support and royalty payments on sales (1/99)

InSite Vision Inc.

SSP Co. Ltd. (Japan)

License agreement/ InSite's AquaSite treatment for dry eye

ND

InSite signed an exclusive licensing agreement granting the Japanese rights to AquaSite to SSP; further details ND (8/99)

Interneuron Pharmaceuticals Inc.

Takeda Chemical Industries Ltd. (Japan)

CerAxon (citicoline), a Phase III product under development for ischemic stroke

$73M

Interneuron will receive $73M in near-term licensing and milestone payments, including $13M in 1999 and $60M for future milestones in the U.S. and Canada; in exchange, Takeda gets exclusive North American commercialization rights; Takeda will also pay royalties to Interneuron, satisfy Interneuron's royatly obligations to Ferrar Internacional S.A., and will fund Phase IV studies in stroke and Phase III trials in other indications (12/99)

Interneuron Pharmaceuticals Inc.

Warner-Lambert Co.

License agreement/ pagoclone, an anxiolytic drug for the treatment of panic and generalized anxiety

$73.75M

Interneuron could receive up to $73.75M, with $13.75M up front and the rest in milestones; in addition Interneuron will receive royalties on any sales; Warner-Lambert will be responsible for all clinical development, regulatory review, manufacturing and marketing for all indications on a worldwide basis (12/99)

IntroGene (the Netherlands)

SyStemix Inc. (affiliate of Novartis AG; Switzerland)

Licensing agreement; SyStemix will license IntroGene's PER.C6 adenoviral packaging cell line for use in producing gene therapy vectors

ND

Novartis will pay up-front fees, annual payments and royalties on sales of adenoviral gene therapy products arising from the agreement (5/99)

Isis Pharmaceuticals

Abbott Laboratories

Abbott will use Isis' Antisense Target Validation technology to prioritize drug development gene targets; Isis will design, screen, synthesize and characterize inhibitors of gene targets provided by by Abbott

ND

Isis will receive an up-front fee, quarterly research fees, milestones and royalties on net sales of any Abbott non-antisense product arising from the collaboration; Isis gets rights to Abbott genes to develop antisense drugs (1/99)

Isis Pharmaceuticals Inc.

Elan Corp. plc (Ireland)

Binding letter of agreement to form a new subsidiary of Isis to develop a platform technology for the oral delivery of antisense drugs; the first project will be an oral formulation of Isis' antisense inhibitor of tumor necrosis factor-alpha

$27M (entire amount is equity investment)

Elan will make a $27M investment in Isis, consisting of $15M in common stock purchased at a premium to market and $12M of convertible exchangeable preferred stock; Elan also will receive warrants exercisable in 5 years; Elan has the right to convert the preferred stock into an ownership interest in either Isis or the new subsidiary (4/99)

Isis Pharmaceuticals Inc.

Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France)

Research collaboration/ Isis' antisense target validation technology

ND

Isis and RPR signed a three-year collaboration agreement to assess genes identified within RPR's genomics programs using Isis' target validation technology; RPR will provide Isis with sequence information on a number of novel gene targets, with the option to expand the number provided; Isis will design optimized antisense inhibitors for these targets, which RPR will use to identify the function of the gene and prioritize the gene targets for development; Isis will develop antisense inhibitors for the targets provided by RPR; RPR will pay Isis research fees and milestone payments based on the success of the collaboration; further financial details ND (9/99)

Karo Bio AB (Sweden)

Abbott Laboratories

Research collaboraation/glucocorticoid receptor antagonists targeting the liver as therapies for diabetes

ND

Abbott gains worldwide marketing rights; Karo receives up-front payments, research funding, milestones and royalties (11/99)

LeukoSite Inc.

Warner-Lambert Co.

Agreement to discover and develop small-molecule antagonists to 2 integrin targets implicated in asthma and inflammatory bowel disease

>$100M

LeukoSite will receive license fees, research support and milestone payments that could exceed $50M for each of the 2 integrin targets, in addition to royalties (1/99)

Lexicon Genetics Inc.

The ParkeDavis pharmaceutical division of Warner-Lambert Co.

Research agreement/ Lexicon's knockout mice

ND

Lexicon and Warner entered an agreement for the rapid engineering of custom knockout mice; Lexicon will produce an undisclosed number of knockout mice using patented technologies in homologous recombination; financial details ND (7/99)

Lexicon Genetics Inc.

BASF Bioresearch Corp. (unit of BASF Pharma; Germany)

Research collaboration/knockout mice creation for validation of target

ND

Lexicon will create knockout mice based on a gene sequence provided by BASF; financial terms ND (12/99)

LifeCell Corp.

Pharmacia & Upjohn

Research collaboration/ LifeCell's ThromboSol

ND

LifeCell will collaborate with P&U and the University of Texas M.D. Anderson Cancer Center to evaluate ThromboSol for the extended storage of platelets; further details ND (7/99)

Ligand Pharmaceueticals Inc.

The ParkeDavis pharmaceutical division of Warner-Lamber Co.

R&D, license agreement/ Estrogen receptor diseases

$13M

Ligand and Parke will collaborate on the discovery, characterization, design and development of small-molecule compounds for the treatment and prevention of diseases mediated through the estrogen receptor; Ligand may receive up to $13M in research funding through September 2002, as well as undisclosed future product milestone payments and royalties; Parke-Davis will fund the costs of developing and marketing compounds selected from the collaboration, and will be granted worldwide rights to manufacture and sell any products resulting from the collaboration; Ligand will be entitled to milestones at various stages of each compound's development, and upon the marketing of a product, will receive royalties on net sales on a product-by-product basis (9/99)

The Liposome Co. Inc.

Bristol-Myers Squibb Co.

Clinical trial collaboration/ Liposome's Evacet and Bristol's Taxol

ND

Liposome and Bristol will collaborate in clinical trials designed to evaluate the safety and efficacy of Evacet in combination with Taxol (paclitaxel) for the treatment of metastatic breast cancer; financial details ND (8/99)

The Liposome Co. Inc.

Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France)

Clinical trial collaboration/ Liposome's Evacet and RPR's Taxotere

ND

Liposome and RPR will collaborate in clinical trials designed to evaluate the safety and efficacy of Evacet in combination with Taxotere (docetaxel) for the treatment of metastatic breast cancer; financial details ND (8/99)

LXR Biotechnology Inc.

RPR Gencell (division of RhonePoulenc Rorer Inc.; subsidiary of Rhone-Poulenc SA)

RPR Gencell will evaluate the cytoprotective role of the SARP-1 gene, discovered by LXR, in heart muscle cells that have been deprived of oxygen

ND

RPR has right of first negotiation to acquire the rights to SARP-1-related technology for cardiovascular indications (1/99)

Metabolex Inc.

Parke-Davis (division of Warner-Lambert Co.)

Research collaboration to discover and develop therapeutics that counteract insulin secretion defects in type 2 diabetes

>$50M

Metabolex will receive an up-front research fee and equity investment, as well as milestones and royalties; pre-commercialization payments could exceed $50M (1/99)

Metabolic Modulators Research Ltd. (Canada)

Chugai Biopharmaceuticals Inc. (subsidiary of Chugai Pharmaceutical Co. Ltd; Japan)

Drug-discovery collaboration and license agreement to develop, manufacture and market therapies for cardiovascular disease; research will center on metabolic modulators; MMR will carry out validation of targets, and Chugai will adapt the targets to its high-throughput screening system; MMR will then profile potential candidates in model systems

ND

Chugai will fund target validation research at MMR and will pay a technology access fee, plus royalties on milestones; Chugai receives worldwide rights to cardiovascular therapies discovered in the collaboration, with the intention of developing and commercializing them; agreement is for 5 years (3/99)

Millennium Predictive Medicine Inc. (subsidiary of Millennium Pharmaceuticals Inc.)

Becton Dickinson and Co.

Five-year alliance to develop Diagnomic (molecular diagnostics) and pharmacogenomic tests for cancer patients

$69.5M (equity; 0.11 voting interest)

Becton Dickinson will provide $15M in equity investment (for an 11% voting interest), a $3M licensing fee, and up to $51.5M in research funding and additional annual licensing fees; Millennium Predictive will receive milestones and royalties on sales (2/99)

Millennium Predictive Medicine Inc.

Bristol-Myers Squibb Co.

Research collaboration/use of pharmacogenomic techniques for new and existing medicines for cancer, along with development of pharmacogenomic diagnostics

$32M

Five-year alliance to identify and validate oncology clinical markers that can help predict patients' responses to existing drugs and aid in the development of new ones; MPMx will receive $32M in license fees, annual fees and research funding, plus milestones and royalties on any products (11/99)

Molecumetics Ltd.
(a subsidiary of Tredegar Corp.)

Pharmacia & Upjohn Co.

Research collaboration/ Molecumetics' SMART Library technology

ND

Molecumetics and P&U entered a research collaboration to identify and develop orally active modulators of caspases; Molecumetics will use its SMART Library technology to optimize lead compounds; P&U will carry out in vivo testing and all preclinical and clinical development activities; Molecumetics will grant P&U worldwide exclusive rights to develop and commercialize the resulting compounds; Molecumetics will receive research funding, milestone payments and royalties from the sales of potential products resulting from the collaboration (9/99)

Multiple Peptide Systems

Elan Corp. plc (Ireland)

Establishment of joint venture for research, development and commercialization of oral and non-oral drug-delivery technologies; MPS will provide combinatorial chemistry capabilities, and Elan will license oral delivery technology to the venture

ND ($5M equity investment)

Joint venture will be a majority-owned subsidiary of MPS and will receive a license from Elan of proprietary oral drug-delivery technology in exchange for a license fee; in a separate transaction, Elan made a $5M equity investment in MPS (4/99)

NaPro Biotherapeutics Inc.

Abbott Laboratories

R&D collaboration/ anticancer therapeutics

ND

NaPro and Abbott entered a long-term collaborative agreement to develop and commercialize one or more formulations of paclitaxel for the treatment of a variety of cancer indications; the agreement covers the U.S. and Canada; NaPro will supply the bulk drug and will jointly conduct the clinical trials with Abbott; Abbott will be responsible for the formulation, regulatory filings, marketing and sale of the finished product; NaPro will license to Abbott its U.S. paclitaxel-related patents, issued and pending, plus any foreign-issued patents, which may apply within the U.S. and Canada; NaPro will receive funding from Abbott in the form of development and marketing milestone payments, a secured loan and an equity investment; Abbott will purchase bulk drug from NaPro and will pay royalties to NaPro from the sale of resulting products (7/99)

NaviCyte Inc. (wholly owned subsidiary of Trega Biosciences Inc.)

Schering-Plough Corp.

Collaboration on use and development of NaviCyte's Pk (pharmacokinetics)Informatics tools to identify drug candidates; ScheringPlough joins consortium supporting development of NaviCyte's In Vitro Determination for Evaluation of Adsorption (IDEA) simulation software system and database; IDEA aims to predict in silico the ADME characteristics of drugs (adsorption, distribution, metabolism and excretion)

ND

Schering-Plough will provide data for IDEA and make initial and milestone payments over the course of development of the software and database; NaviCyte will license to Schering-Plough its software and computational models for use with Schering-Plough compound libraries. (3/99)

NaviCyte Inc. (subsidiary of Trega Biosciences Inc.)

R.W. Johnson Pharmceutical Research Institute (PRI; subsidiary of Johnson & Johnson)

Use and development collaboration centering on NaviCyte's Pk-Informatics tools to identify new candidates for drug development from compound libraries

ND

PRI will provide data and make initial and milestone payments over the course of further development of NaviCyte's In Vitro Determination for Evaluation of Absorption (IDEA) simulation software system and database; NaviCyte will license its software and computational models for use at R.W. Johnson with compound libraries (3/99)

NeoPharm Pharmaceuticals Inc.

Pharmacia & Upjohn Inc.

Definitive agreement for development and commercialization of 2 cancer products: Liposomal Encapsulated Paclitaxel (LEP) and Liposomal Encapsulated Doxorubicin (LED); companies will also work together to identify additional P&U oncology drugs that can be reformulated into NeoPharm's liposome technology

$65M

NeoPharm receives $15M up front as well as milestones in excess of $50M; P&U will pay for all clinical and premarketing expenses; NeoPharm will also receive royalty payments overseas and a co-promotion profit split in the U.S.; P&U gains exclusive worldwide marketing rights (2/22)

Neurochem Inc. (Canada)

H. Lundbeck A/S (Denmark)

Research collaboration/neurological theraapeutics, especially for Alzheimer's disease

$24.5M

Neurochem will receive research support of up to $7.5M over 3 years and up to $17M in milestones; agreement also calls for additional equity investments in Neurochem and royalties on any sales; Lundbeck has exclusive right to develop and commercialize any products resulting from the project, except in Canada, where Neurochem retained co-commercialization rights (11/99)

Neurocrine Biosciences Inc.

Wyeth-Ayerst Laboratories (subsidiary of American Home Products Corp.)

R&D and commercialization agreement on compounds that modulate excitatory amino acid transporters for the treatment of neurodegenerative and psychiatric diseases; companies will share proprietary technologies, including Wyeth's combinatorial chemistry libraries, for screening within the collaborative field

$78M

Neurocrine expects to receive 3 to 5 years of R&D funding, milestones and royalties on resulting products (3/99)

Neurocrine Biosciences Inc.

DuPont Pharmaceuticals Co. and Janssen Pharmaceutica (a subsidiary of Johnson & Johnson)

License agreement

ND

The companies entered a three-way licensing agreement of patents and patent applications relating to a series of small-molecule CRF receptor antagonist compounds; Neurocrine and Janssen receive exclusive rights to a subset of DuPont's CRF antagonist compounds jointly developed by those two companies; Janssen and DuPont agreed to certain milestone payments and royalties on product sales; Neurocrine licensed to DuPont exclusive rights to a subset of CRF receptor antagonist compounds independently developed by Neurocrine; DuPont will make milestone payments to Neurocrine based on the achievement of certain developmental and regulatory goals, and royalty payments based on product sales (9/99)

Neurogen Corp.

Pfizer Inc.

License agreement covering Neurogen's Accelerated Intelligent Drug Discovery (AIDD) technology; Neurogen will install its integrated drug discovery system at Pfizer Central Research; system integrates combinatorial chemistry synthesis, highthroughput screening and informatics to generate drug discovery data in 2 weeks

$27M

Neurogen will receive $27M over 3 years for AIDD installations and enhancements; additional payments possible upon Pfizer's successful utilization of the technology (6/99)

NeXstar Pharmaceuticals Inc.

Fujisawa Pharmaceutical Co. (Japan)

Research collaboration under which NeXstar will use its SELEX process to identify an aptamer as a therapeutic drug candidate to an undisclosed Fujisawa target

ND

Fujisawa has an exclusive option period, upon delivery of the aptamer, to conduct preclinical testing; if the option is exercised, the parties will sign a development license, providing Fujisawa worldwide rights to develop and commercialize the aptamer; NeXstar would receive license fees, milestones and royalties (4/99)

Nortran Pharmaceuticals Inc. (Canada)

Hoechst Marion Roussel (the pharmaceutical subsidiary of Hoechst AG)

Research collaboration/ investigational antiarrhythmic compounds

ND

Nortran and Hoechst will test investigational antiarrhythmic compounds of both companies using their electrophysiological models and other preclinical tests; further details ND (8/99)

Ontogeny Inc.

Tropix (unit of PE Biosystems; subsidiary of Perkin-Elmer Corp.)

Ontogeny transfered assays for a number of validated targets to Tropix for ultrahigh-throughput screening under Xtreme Screen program; the aim is to identify classes of small-molecule leads and extract value from Ontogeny's programs, including the use of smallmolecule receptors and pathways; Tropix will screen combinatorial compound libraries for activity against Ontogeny targets, and will optimize assays to run under ultra-high-throughput screening conditions

ND

ND (1/99)

Onyx Pharmaceuticals Inc.

Warner-Lambert Co.

Development and marketing agreement/ONYX-105 anticancer agent and two additional products

$155M

Onyx will receive an up-front and equity investment over 2 years totaling $15M, plus $40M of support for Phase III costs of ONYX-105; in addition to guaranteed money, Onyx could receive up to $100M in milestones for the three products (10/99)

Orchid Biocomputer Inc.

Beckman Coulter Inc.

Collaboration to combine the companies' technologies to develop a core platform for Orchid's new SNPstream system for genotyping single nucleotide polymorphisms, slated for a fall 1999 launch

ND

ND (3/99)

OSI Pharmaceuticals Inc.

Tanabe Seiyaku Co. Ltd. (Japan)

R&D collaboration/ small-molecule drugs for treatment of Type II diabetes mellitus

ND

OSI formed a strategic partnership with Tanabe to discover and develop smallmolecule drugs for the treatment of Type II diabetes mellitus; OSI will receive an up-front fee, support for a four-year funded research program, and milestone, success payments and royalties on successful product development; successful development could result in over $30M of milestone payments and success fees over and above royalties, for each target in the multi-target program (9/99)

OXiGENE Inc. (Sweden)

Bristol-Myers Squibb Co.

Licensing agreement and research collaboration/combretastatin antitumor vascular targeting agents

$70M

BMS licensed worldwide rights to develop compounds in this class, including lead compound Combretastatin A4 Prodrug; BMS will provide up to $70M in licensing fees, including up-front payment, development milestones and research funding, as well as royalties on any sales (12/99)

Paratek Pharmaceuticals Inc.

Glaxo Wellcome plc

R&D collaboration/ antibiotic targeting multiple antibioticresistant bacteria

ND

Paratek and Glaxo entered a collaboration to develop and commercialize new antibiotics targeting multiple antibiotic-resistant bacteria; the agreement includes equity investments, research support, milestone payments and royalties; further details ND (7/99)

Pentose Pharmaceuticals Inc.

Cangene Corp. (Canada)

Development, manufacturing and license agreement; companies will perform collaborative research to assess and develop the use of Pentose's Inactine (which targets viruses in blood products) with Cangene's hyperimmune products

ND

Cangene receives a non-exclusive worldwide license to use Inactine in plasma-derived therapeutic proteins; Pentose receives an upfront licensing fee and also will receive milestone payments and royalties (4/99)

Pharmacopeia Inc.

Pharmacia & Upjohn Inc.

Pharmacopeia will screen its multi-million compound sample collection of diverse, small molecules against P&U targets; optimization of active compounds may be performed by P&U or by Pharmacopeia for additonal consideration

ND

Multi-year agreement with guaranteed annual payments and further payments based on the success of the screening programs (1/99)

Pharmacopeia Inc.

Hoffmann-La Roche Inc. (a member of the Roche group)

Research collaboration/ Pharmacopeia's Melanocortin-4 (MC-4)

ND

Pharmacopeia and Roche entered a research collaboration focusing on small-molecule agonists for MC-4; Roche will provide Pharmacopeia with research funding to pursue further chemical optimization of the lead compounds identified by Pharmacopeia; the two companies will collaborate in an effort to identify a clinical candidate to be developed and commercialized by Roche; financial details ND (10/99)

Pharmacopeia Inc.

Otsuka Pharmaceutical Factory Inc. (division of Otsuka Group; Japan)

Research collaboration/lead discovery services that include assay development

ND

Pharmacopeia will receive fees, milestones and royalties on marketed products (11/99)

Pharmacopeia Inc.

Organon (unit of Akzo-Nobel; the Netherlands)

Screening agreement/screening of 2.7M small molecules against Organon targets

ND

Pharmacopeia will receive fees for services, milestones and royalties on sales (10/99)

Pharmasset Ltd.

DuPont Pharmaceuticals Co.

R&D collaboration/HIV and hepatitis B antiviral compounds

$30M

Pharmasset and DuPont entered a collaboration to create and identify novel nucleoside reverse transcriptase inhibitors to be developed and commercialized by DuPont; the agreement includes an equity investment, up-front payment, research support and milestones and royalties on products resulting from the collaboration (9/99)

Photogen Technologies Inc.

Akorn Inc.

Development collaboration/certain formulations of photoreactive compound PH-10, a potential treatment for cancer and certain dermatological conditions

ND

Akorn will help Photogen meet regulatory requirements of the FDA and will develop formulations geared toward various indications; financial terms ND (11/99)

Physiome Sciences Inc.

PA Consulting Group

Joint project to create in silico human body systems by designing and building a computer model of immune systems; goal is to build a “virtual human body“ for use in pharmaceutical and biomedical research; Physiome will acquire Organ Systems Modelling, a PA subsidiary, which holds exclusive license to PA health care software

$10M ($5M equity)

Physiome will receive $10M over 18 months, half in research support and half in equity; under certain unspecified conditions, PA will invest an additional $5M in Physiome (5/99)

PolyMasc Pharmaceuticals plc (UK; acquired by Valentis Inc.)

The pharmaceutical division of Bayer Corp. (Germany)

Research agreement/ PolyMasc's ProtoMasc technology

ND

Bayer will fund a feasibility study on the development of Factor VIII using PolyMasc's ProtoMasc technology in order for Bayer to determine whether to enter a broader agreement leading to clinical and commercial development of a chemically modified Factor VIII; financial details ND (8/99)

POZEN Inc.

F. Hoffmann-La Roche Ltd. (Switzerland)

License agreement/novel serotonin (5-HT2B) receptor antagonist discovered by Roche

ND

POZEN acquired exclusive worldwide license and has assumed full responsibility for development, regulatory approval and commercialization; POZEN will pay “certain consideration“ upon commercialization; Roche has option to reacquire product at pre-agreed times subject to payment of milestones and royalties to POZEN (11/99)

PPL Therapeutics plc (UK)

Smith & Nephew plc (UK)

R&D collaboration covering PPL's recombinant fibrin sealant wound care product; the companies will jointly develop a range of orthopedics products using PPL's production technology

ND

S&N will make a payment on signing the supply agreement for the supply of materials during the 1st phase of the collaboration, with further milestone payments possible, along with royalties (3/99)

ProCyte Corp.

Neutrogena Corp. (subsidiary of Johnson & Johnson)

Neutrogena will evaluate ProCyte's copper peptide complexes for hair and skin products

ND

Companies signed 2 agreements; the first is an option and product study agreement for ProCyte's AHK:cu technology for consumer hair products; the second is a product study agreement for ProCyte's GHK:cu technology for skin care products (2/99)

Proliferon Inc.

SmithKline Beecham plc (UK)

Research collaboration/use of directed combinatorial chemistry libraries and highthroughput screening assays to identify drug candidates

ND

SmithKline gets worldwide rights to develop and market products identified by Proliferon; Proliferon will receive up-front research payments and royalties on sales of pharmaceutical products (11/99)

Protein Design Labs Inc.

ND

License agreement/ PDL's antibody humanization patents

ND

PDL signed a patent license agreement with a major, undisclosed pharmaceutical company for certain non-exclusive rights under PDL's antibody humanization patents to an antibody in clinical development; PDL will receive a non-refundable, noncreditable fee, annual maintenance fees and potential royalties on sales of the antibody; further details ND (9/99)

Protein Design Labs Inc.

SmithKline Beecham

License agreement/ SmithKline's humanized antibody to interleukin-4 (anti-IL-4) and PDL's antibody humanization patents for its humanized antibody to interleukin-5 (anti-IL-5)

ND

PDL obtained a license to SB's anti-IL-4; PDL granted an exclusive license under its humanization patents to SB for antiIL-5; PDL will complete a Phase I trial for anti-IL-4 and conduct Phase II trials in asthma patients; SB will manufacture the antibody for the trials; PDL will be entitled to exclusive, worldwide development, marketing and sales rights to the anti-IL-4 antibody unless SB pays an opt-in fee at the end of Phase II clinical development; if SB elects to participate, the two companies will share future development costs and profits at an agreed-upon ratio; PDL may also receive certain co-promotion rights in the U.S. (9/99)

Protherics plc (UK; created by merger of Proteus International and Therapeutic Antibodies Inc.)

Eli Lilly and Co.

Licensing agreement and research collaboratiohn/existing Factor Xa inhibitor leads and identification of new ones using Protherics' Computer Aided Design technology

$5M

During the initial 2 years of the agreement, Protherics may receive more than $5M in initial license fees, research funding and milestones; total payments could be much higher; Protherics would also receive royalties on any sales; financial details ND (12/99)

Quark Biotech Inc.

Sankyo Co. Ltd. (Japan)

Sankyo will use Quark's pathology-specific gene discovery technology and model systems to study gene responses and identify candidates for Type II diabetes; Quark will initially conduct a feasibility study to determine the insulin response pathways in specific target cells; over long term, Quark will perform high-throughput gene discovery using functional and differential expression profiling in animal models

ND

Payments to Quark include milestones and royalties (2/99)

Quark Biotech Inc.

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Gene discovery research collaboration; Quark will use its pathology-specific genomics and bioinformatics technology to work with Fujisawa on the discovery of genes for use as targets for the development of stroke therapeutics

$19M

Fujisawa will provide research funding and pay milestones and royalties; Fujisawa gains worldwide development, manufacturing and marketing rights on the resulting products; Quark has an option to co-market certain products in the U.S. and Europe (4/99)

Quark Biotech Inc.

Sankyo Co. Ltd. (Japan)

Research and license agreement/Quark's gene discovery technology

ND

Quark will use its gene discovery technology to identify key genes and pathways responsible for apoptosis of particular cells and tissues caused by certain autoimmune disease, identify candidates for drug development, and eventually commence clinical testing for selected therapeutic candidates; Sankyo will have exclusive rights to market products resulting from the collaboration; Quark will be entitled to research and development payments, milestone payments and royalties (9/99)

Quark Biotech Inc.

Taisho Pharmaceutical Co. Ltd. (Japan)

Research and license agreement/identification and analysis of genes and pathways involved in renal diseases

ND

Quark has rights to co-market resulting products in North America and the European Union, and is entitled to R&D funding and milestone payments, as well as royalties on any products (12/99)

Ribozyme Pharmaceuticals Inc.

Eli Lilly and Co.

R&D collaboration on ribozymes for the treatment of hepatitis C infection

$38M

Ribozyme will receive $9.2M in 1999, which includes initial fees, research funding, funding for clinical trial materials and an equity investment; Ribozyme could eventually receive up to $38M, primarily from milestones, plus additional royalties; Lilly gains exclusive worldwide commercialization rights to products (3/99)

Ribozyme Pharmaceuticals Inc.

Elan Corp. plc (Ireland)

Joint venture/Herzyme, a ribozyme against human epidermal growth factor receptor Type 2 (HER-2) for treatment of breast and other cancers

ND

Venture will license Elan's MEDIPAD Drug Delivery System for development in conjunction with Herzyme, which is being contributed by Ribozyme; Ribozyme may fund its share of development costs through sale of preferred stock to Elan; in addition, Elan will purchase Ribozyme common stock as part of the agreements; additional details will be disclosed when deal is finalized (12/99)

Rigel Inc.

Janssen Pharmaceutica NV (subsidiary of Johnson & Johnson)

Collaboration to identify drug targets that control progression of cancer based on Rigel's functional genomics technology; efforts will focus on discovery and validation of smallmolecule drug targets that regulate cell cycle; collaboration also covers predictive, diagnostic and protein therapeutic utility of targets

ND

Janssen will provide research funding for a minimum of 3 years, as well as a cash up-front payment and milestones; Rigel would also receive royalties; the Johnson & Johnson Development Corp. is participating in Rigel's Series D financing; Janssen gets exclusive worldwide rights to develop and market drugs against the cell cycle regulating targets and will also have nonexclusive rights to the use of some Rigel technology to discover targets in other areas of cancer therapy in exchange for milestones and royalties on sales (1/99)

Rigel Inc.

Novartis AG (Switzerland)

Research collaboration under which companies will work together on 5 different 5-year research projects to identify drug targets; initial project focuses on targets that regulate T cells; Novartis will decide on the others within 2 years

ND (equity component)

Rigel will receive up-front cash and equity investment, research funding and milestones, and potential royalties; equity investment consists of “significant immediate funding,“ but the majority is callable by Rigel up through an IPO (6/99)

Sangamo BioSciences Inc.

DuPont Pharmaceuticals Co.

DuPont will use Sangamo's Universal GeneTools platform in the identification and validation of gene targets for drug discovery; platform enables rational design and rapid generation of ZFP transcription factors that can recognize and regulate target gene or DNA sequence

ND

DuPont will provide funding in exchange for using Sangamo's technology (1/99)

Sangamo BioSciences Inc.

Japan Tobacco Inc.

Japan Tobacco will use Sangamo's Universal GeneTools platform in the identification and validation of gene targets for drug discovery; platform enables rational design and rapid generation of ZFP transscription factors that can recognize and regulate target gene or DNA sequence

ND

Japan Tobacco will provide funding in exchange for using Sangamo's technology (3/9)

Sangamo BioSciences Inc.

F. Hoffmann-La Roche Ltd. (Switzerland)

Research collaboration under which Sangamo will provide specific Universal GeneTools to Roche for evaluation in transgenic mouse systems; the GeneTools platform enables rational design and rapid generation of highly specific zinc finger DNA recognition proteins that can recognize and regulate any target gene or DNA sequence

ND

ND (6/99)

Sangamo Biosciences Inc.

Schering AG (Germany)

Research agreement/ Sangamo's Universal GeneTools technology

ND

Sangamo and Schering signed a collaborative research agreement under which Sangamo will provide specific Universal GeneTools to Schering for evaluation in its research programs; further details ND (8/99)

Sangamo Biosciences Inc.

Merck KgaA (Germany)

Research collaboration/use of Universal GeneTools, which enable rapid generation of highly specific zinc finger DNA binding protein transcription factors that can recognize and regulate target DNA sequence

ND

Merck will use the technology in its internal research and validation programs; terms were not disclosed (11/99)

Sequitur Inc.

Pharmacia & Upjohn

Technology access agreement/Sequitur's antisense functional genomics technology

ND

Sequitur and P&U signed a multiyear agreement under which P&U will have access to Sequitur's antisense functional genomics technology; further details ND (9/99)

Sequitur Inc.

Searle (the pharmaceutical division of Monsanto Co.)

Technology access agreement/Sequitur's antisense functional genomics technology

ND

Sequitur and Searle signed a multi-year agreement under which Searle will have access to Sequitur's antisense functional genomics technology; the agreement provides for the supply of Sequitur's antisense compounds, sequence selection and cellular delivery vehicles to Searle, as well as collaborative research to be performed at Sequitur; Searle will pay research support, antisense material charges and licensing fees (10/99)

Scotia Holdings plc (UK)

Bristol-Myers Squibb Co.

R&D collaboration; Scotia will develop prototype formulations, using its Galactosome technology, for a number of Bristol-Myers molecules

ND

Bristol-Myers will fund initial feasibility studies and has the option to develop any of the prototype formulations; at a later date, Bristol-Myers and Scotia may enter development and licensing agreements, providing for milestones and royalties (4/99)

Scriptgen Pharmaceuticals Inc.

DuPont Pharmaceuticals Co.

Antibacterials collaboration; collaboration includes transfer of Scriptgen's lead series of antibacterial compounds as well as screening of compounds from both Scriptgen's and DuPont's compound libraries; Scriptgen will provide access to its ATLAS and SCAN assay technologies to identify compounds that bind to protein or RNA targets respectively, and to its GATE technology, a family of high-throughput target and validation technologies; DuPont is responsible for lead optimization chemistry and all preclinical and clinical development

$53M (equity; % ND)

DuPont committed $8M to gain access to Scriptgen's assay, screening and validation technologies; the $8M combines an up-front payment and purchase of Scriptgen capital stock at the time of its IPO; Scriptgen will also receive research and milestone payments and royalties on products; with 2 successful products, the total could exceed $53M plus royalties (1/99)

Sibia Neurosciences Inc.

American Home Products Corp.

Licensing agreement for Sibia's transcription-based assay patent portfolio; technology uses transcription of a reporter gene to identify compounds that modulate cell activity

ND

Sibia will receive annual maintenance payments and potential royalties; AHP's license is non-exclusive (6/99)

Sibia Neurosciences Inc.

Bristol-Myers Squibb Co.

Licensing agreement for Sibia's transcription-based assay patent portfolio; technology uses transcription of a reporter gene to identify compounds that modulate cell activity

ND

Sibia will receive annual maintenance payments and potential royalties; BristolMyers' license is non-exclusive (3/99)

Sibia Neurosciences Inc.

SmithKline Beecham plc (UK)

Licensing agreement for Sibia's transcription-based assay patent portfolio; technology uses transcription of a reporter gene to identify compounds that modulate cell activity

ND

Sibia will receive annual maintenance payments and potential royalties; SmithKline's license is non-exclusive (3/99)

Sibia Neurosciences Inc.

Pharmacia & Upjohn

License agreement/ Sibia's transcription-based assay patent portfolio

ND

Sibia and P&U entered a non-exclusive license agreement for Sibia's transcriptionbased assay patent portfolio; P&U and its affiliates receive a worldwide license to drug discovery technology that uses transcription-based assays for identifying compounds that modulate cell surface protein activity; Sibia will receive annual maintenance payments, as well as royalties on sales of any compounds resulting from the agreement (7/99)

SkyePharma plc (UK)

SmithKline Beecham (UK)

Development and licensing agreement/SB's Requip and SkyePharma's Geomatrix oral delivery technology

$8M

SB and SkyePharma entered a development and licensing agreement for a once-daily version of SB's anti-Parkinsonian drug Requip (ropinirole), using SkyePharma's Geomatrix oral delivery technology; SkyePharma will be responsible for all development activities up to regulatory filing in collaboration with SB; SB will make an equity investment of $8M in SkyePharma; SkyePharma will receive milestone payments at intervals up to product approval, including an up-front payment; upon commercialization of once-daily Requip, SkyePharma will receive royalties on product sales (9/99)

Stem Cell Sciences (Australia)

Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France)

Gene and drug screening collaboration/Stem Cell's gene screening technology

$1.5M

Stem Cell will provide RPR with its gene screening technology to functionally validate neuroprotective genes and genetically engineered cells for use in its Alzheimer's drug discovery program; RPR will pay Stem Cell $1.5M in up-front and milestone payments in return for a non-exclusive license to use Stem Cell's technology; further details ND (8/99)

Structural Bioinformatics Inc.

DuPont Pharmaceuticals Co. (unit of DuPont Co.)

R&D collaboration for discovery and development of small-molecule leads in a family of signaling proteins and other targets; DuPont will assume responsibility for preclinical discovery and development of leads arising from the collaboration, as well as small-molecule leads previously identified by SBI

$100M

Multiyear agreement includes guaranteed and milestone payments with an overall value in excess of $100M if several successful products are developed; DuPont will pay for technology access and provide research support; DuPont has worldwide rights to all products arising from the program, and SBI will receive milestones and royalties from any drugs commercialized from these activities (5/99)

Synergy Vaccines Inc.

Becton Dickinson Technologies

R&D collaboration using SynerVax, Synergy's vaccine adjuvant technology, to develop a vaccine

ND

Becton will fund development and has an option agreement to license the vaccine in Asia and Africa (3/99)

Targeted Genetics Corp.

Elan Corp. plc

Development agreement/ gene delivery technology

$22M

Targeted and Elan signed definitive agreements to form a new subsidiary of Targeted Genetics, to be called Emerald Gene Systems, for the enhanced delivery of therapeutic genes; Targeted will own 81% of the new company, subject to completion of appropriate trademark searches; Elan will make an initial $5M investment in Targeted common stock at a premium to market price, and will purchase an additional $5M of common stock at a premium to market one year from the date of the agreements; additionally, Elan will purchase $12M of Targeted convertible exchangeable preferred stock; Elan has the right to either convert the preferred stock into additional common shares or exhange it for increased ownership in Emerald to 50% (7/99)

Telik Inc.

Sankyo Co. Ltd. (Japan)

R&D collaboration; Telik will use its TRAP chemoinformatics drug-discovery technology to screen its small-molecule library against up to 10 Sankyo targets

ND

Telik will receive up-front payments; Sankyo will have the option to acquire an exclusive worldwide license to develop and commercialize any or all of the identified molecules (4/99)

Targacept Inc. (wholly owned subsidiary of R.J. Reynolds Tobacco Co., a subisidary of RJR Nabisco Inc.)

Rhone-Poulenc Rorer Inc. (subsidiary of RhonePoulenc SA; France)

Collaboration on R&D and commercialization of certain nicotinic com pounds for Alzheimer's and Parkinson's diseases

ND (potential equity)

RPR has exclusive global rights to compounds covered in the collaboration; Targacept will receive license fees, milestones and royalties, as well as a potential equity investment (2/99)

Techniclone Corp.

Schering AG (Germany)

Collaboration on Techniclone's Oncolym, a radiolabeled monoclonal antibody in Phase II/III for the treatment of intermediate and high-grade non-Hodgkin's B-cell lymphoma

$20M

Schering will pay Techniclone a $3M up-front fee, plus $17M for milestones and capital costs for commercial radiolabeling scale-up; Schering will also assume 80% of the existing clinical trial costs and pay royalties; Techniclone will manufacture the drug and receive a margin above production cost; Schering gets exclusive worldwide marketing and distribution rights (3/99)

TerraGen Discovery Inc. (Canada)

Schering-Plough Research Institute (unit of ScheringPlough Corp.)

Parties agreed to a 2nd collaboration, to discover antiinfective compounds; TerraGen will apply its lead discovery capabilities to identify small-molecule lead compounds from its NatChem library of microbial extracts

ND

TerraGen will receive research funding, milestones and potential royalties (6/99)

Third Wave Technologies Inc.

Parke-Davis pharmaceutical division of Warner-Lambert Co.

Technology access agreement/Third Wave's Invader assay portfolio

ND

Third Wave will provide Warner with a portfolio of Invader assays for evaluation in genotyping and gene expression applications; Third Wave will own improvements to its technology and will receive exclusive access to discoveries made using the Invader assays for diagnostic applications; financial details ND (9/99)

Transkaryotic Therapies Inc.

Sumitomo Pharmaceuticals Co. Ltd. (Japan)

Collaboration to commercialize Transkaryotic's alpha-galactosidase A enzyme replacement therapy for Fabry disease in Japan and other Far East territories

$2M

Sumitomo paid Transkaryotic $2M up front and will make additional payments as the product moves through development and commercialization (1/99)

Triangle Pharmaceuticals Inc. and Emory University

Glaxo Wellcome Inc. and Glaxo Group Ltd. (units of Glaxo Wellcome plc)

Glaxo granted worldwide, exclusive license to Triangle and Emory, giving them access to development and clinical data, drug substance and patent property associated with Coviracil, an antiviral nucleoside analogue active against HIV and hepatitis B virus; agreement resolves legal disputes related to the product, which Emory first licensed to Glaxo, then to Triangle

ND

ND (5/99)

Valentis Inc.

Boehringer Ingelheim International GmbH (Germany)

Research collaboration/ Valentis' delivery and expression systems and Boehringer's proprietary genes in animal models of rheumatoid arthritis (RA)

ND

The two companies will conduct evaluations of Valentis' delivery and expression systems in combination with Boehringer's proprietary genes in animal models of RA; Boehringer will provide research support to Valentis for up to 15 months for work performed under the collaboration; financial details ND (9/99)

Versicor Inc.

Novartis AG (Switzerland)

Research collaboration to discover new antibacterials that inhibit deformylase and the Mur pathway using Versicor's assays

$38M

Three-year deal includes up-front payment, plus equity, research funding, milestones and royalties; Versicor has co-promotion rights for the North American hospital sector (3/99)

Versicor Inc.

Pharmacia & Upjohn

Research collaboration to discover new oxazolidinones, a new class of antibacterials; program will use Versicor's infectious disease-oriented biology and combinatorial chemistry technology platforms

ND

Versicor will receive up-front cash, equity payments and research funding over the course of 2 to 3 years; the deal also includes additional equity and potential milestones and royalties (4/99)

Versicor Inc.

Eli Lilly and Co.

Licensing agreement under which Versicor gains rights to LY303366, a semi-synthetic antifungal derivative of echinocandin B

ND

Lilly will receive a signing fee, milestones and royalties; Lilly also retains option to develop oral formulation; in exchange, Versicor will receive exclusive worldwide commercialization rights and will be responsible for development and clinical registration work (6/99)

Vertex Pharmaceuticals Inc.

Taisho Pharmaceutical Co. Ltd. (Japan)

R&D collaboration/ discovery and development of caspase inhibitors for treatment of cerebrovascular, cardiovascular and neurodegenerative diseases; caspases involved in apoptosis will be a focus area

$43M

Vertex will receive initial payments of $4M, research funding and milestones from Taisho, which will also pay for up to one-third of the cost of developing compounds that emerge from the program; Taisho gains option for marketing rights for any such compound in Japan and certain Far East markets; deal does not include rights to Vertex's ICE (caspase-1) program (11/99)

ViroPharma Inc.

Battelle Pulmonary Therapeutics (division of Battelle Memorial Institute*)

License agreement/ Battelle's inhalation drug delivery device technology for use in combination with ViroPharma's small-molecule antiviral drug candidates for treating respiratory syncytial virus

ND

ViroPharma is responsible for development, manufacturing and commercialization of all RSV products; financial terms of license agreement ND (12/99)

ViroPharma Inc.

Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Products Corp.)

Development and commercialization agreement/small-molecule antiviral drug candidates for hepatitis C virus

$5M

Companies will co-promote products and share equally in profits from sales in the U.S. and Canada; in the rest of the world, Wyeth-Ayerst will assume full responsibility for commercialization; ViroPharma will receive up-front fee of $5M, plus milestones, research funding, and equity investments (12/99)

Xenometrix Inc.

SmithKline Beecham plc (UK)

Xenometrix granted Smith Kline nonexclusive license to gene profiles utilizing all methods including highdensity microarrays

ND

ND

Xenometrix Inc.

Motorola Inc.

Licensing agreement granting Motorola access to Xenometrix's patent claims for collecting gene expression profiles utilizing all platforms, including microarrays

ND

Non-exclusive license; further details ND (4/99)

XTL Biopharmaceuticals Ltd. (Israel)

Eli Lilly & Co.

Research agreement/ XTL's model for hepatitis C

ND

XTL will test a Lilly drug candidate in its proprietary animal model for hepatitis C; further details ND (9/99)

XTL Biopharmaceuticals Ltd. (Israel)

F. Hoffmann-La Roche Ltd. (Switzerland)

Research collaboration/ use of Trimera mouse model of hepatitis C to test Roche compounds

ND

Roche will use Trimera to test compounds; financial terms ND (11/99)

Zycos Inc.

Pasteur Merieux Connaught (a unit of RhonePoulenc SA France)

R&D collaboration/ Zycos' Epiquest antigen database

ND

Zycos and Pasteur will collaborate to identify antigens that may play a role in fighting cancer using Zycos' epitope discovery program; further details ND (8/99)ND (8/99)


Back to Top

No Comments
BioWorld MedTech